Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||GS-9716 + Sacituzumab govitecan-hziy|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|GS-9716||GS 9716|GS9716||MCL1 Inhibitor 18||GS-9716 inhibits MCL1, potentially leading to decreased tumor cell viability and inhibition of tumor growth and tumor regression (Cancer Res 2022;82(12_Suppl):Abstract nr 3696).|
|Sacituzumab govitecan-hziy||Trodelvy||IMMU-132|Sactizumab|Sacituzumab govitecan||TROP2 Antibody 7||Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate composed of a monoclonal anti-TROP2 antibody linked to the active metabolite of irinotecan (SN-38), which binds to TROP2 positive cancer cells and induces DNA breakage and apoptosis (PMID: 26541586). Trodelvy (sacituzumab govitecan-hziy) is FDA approved for use in patients with metastatic triple-negative breast cancer who received two or more prior therapies, in patients with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies, and in patients with locally advanced or metastatic urothelial cancer who received a platinum-containing chemotherapy and a PD-1 orPD-L1 inhibitor (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05006794||Phase I||GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716||Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies||Recruiting||USA||0|